Preferences help
enabled [disable] Abstract
Number of results
2002 | 49 | 1 | 93-98
Article title

Cross-resistance to five glucocorticoids in childhood acute lymphoblastic and non-lymphoblastic leukemia samples tested by the MTT assay: Preliminary report.

Title variants
Languages of publication
In vitro antileukemic activity of five glucocorticoids and their cross-resistance pattern in childhood acute lymphoblastic and non-lymphoblastic leukemia were determined by means of the MTT assay in 25 leukemia cell samples of childhood acute leukemias. The equivalent antileukemic concentrations of the drugs tested were: 34 μM hydrocortisone (HC), 8 μM prednisolone (PRE), 1.5 μM methylprednisolone (MPR), 0.44 μM dexamethasone (DX) and 0.22 μM betamethasone (BET). In comparison with initial ALL cell samples, the relapsed ALL group was more resistant to PRE (38-fold, p = 0.044), DX (> 34-fold, p = 0.04), MPR (38-fold), BET (45-fold) and HC (33-fold). The AML cell samples were even more resistant to: PRE (>85-fold, p=0.001), DX (> 34-fold, p = 0.004), MPR (> 69-fold, p = 0.036), BET (> 69-fold, p = 0.038) and HC (54-fold, p = 0.059) when compared with ALL on initial diagnosis. A significant cross-resistance among all the glucocorticoids used was found. Only in some individual cases the cross-resistance was less pronounced.
Physical description
  • 1. Kaspers, G.J., Pieters, R., Klumper, E., De Waal, F.C. & Veerman, A.J. (1994) Glucocorticoid resistance in childhood leukemia. Leuk. Lymphoma. 13, 187-201.
  • 2. Schrappe, M., Reiter, A., Ludwig, W.D., Harbott, J., Zimmermann, M., Hiddemann, W., Niemeyer, C., Henze, G., Feldges, A., Zintl, F., Kornhuber, B., Ritter, J., Welte, K., Gadner, H. & Riehm, H. (2000) Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: Results of trial ALL- BFM German-Austrian-Swiss ALL-BFM Study Group. Blood 95, 3310-3322.
  • 3. Kofler, R. (2000) The molecular basis of glucocorticoid-induced apoptosis of lymphoblastic leukemia cells. Histochem. Cell Biol. 114, 1-7.
  • 4. Longui, C.A., Vottero, A., Adamson, P.C., Cole, D.E., Kino, T., Monte, O. & Chrousos, G.P. (2000) Low glucocorticoid receptor alpha/beta ratio in T-cell lymphoblastic leukemia. Hormone Metab. Res. 32, 401-406.
  • 5. Gruol, D.J., Vo, Q.D. & Zee, M.C. (1999) Profound differences in the transport of steroids by two mouse P-glycoproteins. Biochem. Pharmacol. 58, 1191-1199.
  • 6. Hala, M., Hartmann, B.L., Bock, G., Geley, S. & Kofler, R. (1999) Glucocorticoid-receptor- gene defects and resistance to glucocorticoid-induced apoptosis in human leukemic cell lines. Int. J. Cancer. 68, 663-668.
  • 7. Biswas, T., Ramana, C.V., Srinivasan, G., Boldogh, I., Hazra, T.K., Chen, Z., Tano, K., Thompson, E.B. & Mitra, S. (1999) Activation of human O6 -methylguanine-DNA methyltransferase gene by glucocorticoid hormone. Oncogene 18, 525-532.
  • 8. Creagh, E.M., Sheehan, D. & Cotter, T.G. (2000) Heat shock proteins - modulators of apoptosis in tumour cells. Leukemia 14, 1161-1173.
  • 9. Ito, C., Evans, W.E., McNinch, L., Coustan- Smith, E., Mahmoud, H., Pui, C.H. & Campana, D. (1996) Comparative cytotoxicity of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia. J. Clin. Oncol. 14, 2370-2376.
  • 10. Kaspers, G.J., Veerman, A.J., Popp-Snijders, C., Lomecky, M., Van Zantwijk, C.H., Swinkels, L.M., Van Wering, E.R. & Pieters, R. (1996) Comparison of the antileukemic activity in vitro of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia. Med. Pediatr. Oncol. 27, 114-121.
  • 11. Mihal, V., Hajduch, M., Noskova, V., Feketova, G., Jess, K., Gojova, L., Kasparek, I., Stary, J., Blazek, B., Pospisilova, D. & Novak, Z. (1999) Differential antileukemic activity of prednisolone and dexamethasone in freshly isolated leukemic cells. Adv. Exp. Med. Biol. 457, 461-471.
  • 12. Styczyński, J., Pieters, R., Huismans, D.R., Schuurhuis, G.J., Wysocki, M. & Veerman, A.J.P. (2000) In vitro drug resistance profiles in adult versus childhood acute lymphoblastic leukaemia. Br. J. Haematol. 110, 813-818.
  • 13. DeRijk, R. & Sternberg, E.M. (1997) Corticosteroid resistance and disease. Ann. Med. 29, 79-82.
  • 14. Lamberts, S.W.J., Huizinga, A.T.M., De Lange, P., De Jong, F.H. & Koper, J.W. (1996) Clinical aspects of glucocorticoid resistance. Steroids. 61, 157-160.
  • 15. Hongo, T., Yamada, S., Yajima, S., Watanabe, C., Fuji, Y., Kawasaki, H., Yazaki, M., Hanada, R. & Horikoshi, Y. (1999) Biological characteristics and prognostic value of in vitro three-drug resistance to prednisolone, L-asparaginase, and vincristine in childhood acute lymphoblastic leukemia. Int. J. Hematol. 70, 268-277.
  • 16. Schwartz, C.L., Thompson, E.B., Gelber, R.D., Young, M.L., Chilton, D., Cohen, H.J. & Sallan, S.E. (2001) Improved response with higher corticosteroid dose in children with acute lymphoblastic leukemia. J. Clin. Oncol. 19, 1040-1046.
  • 17. Zwaan, C.M., Kaspers, G.J.L., Pieters, R., Ramakers-Van Woerden, N.L., Den Boer, M.L., Wunsche, R., Rottier, M.M.A., Hahlen, K., Van Wering, E., Janka-Schaub, G.E., Creutzig, U. & Veerman, A.J.P. (2000) Cellular drug resistance profiles in childhood acute myeloid leukemia: Differences between FAB types and comparison with acute lymphoblastic leukemia. Blood. 96, 2879-2886.
Document Type
Publication order reference
YADDA identifier
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.